Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myelomaA. Keith Stewart, Jesús G. Berdeja, Amrita Krishnan et al.|Blood Cancer Journal|2019Cited by 62
Data from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin LymphomaDongwei Li, Andrew G. Polson, Kirsten Achilles Poon et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin LymphomaDongwei Li, Andrew G. Polson, Kirsten Achilles Poon et al.|Unknown|2023Cited by 0
Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin LymphomaDongwei Li, Andrew G. Polson, Kirsten Achilles Poon et al.|Unknown|2023Cited by 0
Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin LymphomaDongwei Li, Andrew G. Polson, Kirsten Achilles Poon et al.|Unknown|2023Cited by 0